ERCC2 and non-small cell lung carcinoma: By pooling dataset of 24 studies investigating the predictive role of XPD Asp312Asn (G>A) and Lys751Gln (A>C) in clinical outcome of NSCLC patients treated with platinum regimen, we found that none of the two polymorphisms was related to TR, PFS or OS in overall population, which is consistent with the findings of the previous meta-analysis by Ming Yin et al. [26].